Subtypes & Risk Factors of Vascular Cognitive Impairment

Vascular cognitive impairment (VCI) encompasses the full spectrum of cerebrovascular-related cognitive decline, from mild vascular cognitive impairment with preserved daily function to major vascular cognitive impairment (vascular dementia) and mixed-etiology dementias. Community-based autopsy series demonstrate that mixed pathologies — most commonly Alzheimer disease (AD) combined with cerebrovascular disease — are more prevalent than any single pathology alone. Cerebrovascular disease lowers the threshold for the clinical expression of dementia when other pathologies coexist, and each additional vascular insult further reduces brain resilience. Vascular dementia accounts for approximately 20% of all dementia cases, although this figure likely underestimates the true contribution because it excludes mild VCI and mixed dementias. Because cerebrovascular disease is associated with modifiable risk factors, it represents a critical target for prevention strategies.

VCI Classification and Subtypes

The Vascular Impairment of Cognition Classification Consensus Study (VICCCS) harmonized clinical and research criteria for VCI using a Delphi approach with multinational clinicians and researchers. Mild VCI requires impairment in at least one cognitive domain with mild or no functional decline in instrumental or basic activities of daily living (ADL). Major VCI (vascular dementia) requires cognitive deficits in at least one domain plus severe disruption to instrumental or basic ADLs independent of stroke-related motor or sensory deficits. Neuroimaging evidence of cerebrovascular disease — preferably by MRI due to its superior sensitivity for small vessel disease — is required for a diagnosis of probable VCI. Major VCI subtypes include post-stroke dementia, subcortical ischemic vascular dementia, multi-infarct (cortical) dementia, and dementias due to mixed pathologies.

Post-Stroke Dementia

Stroke is one of the strongest risk factors for VCI. Post-stroke cognitive impairment affects up to 60% of stroke survivors in the first year, mostly within the first 6 months. Stroke doubles the risk of dementia, with hemorrhagic stroke conferring higher risk than ischemic stroke. Risk factors for post-stroke dementia include greater age, larger stroke volume, pre-existing small vessel disease on MRI, brain atrophy, diabetes, low educational attainment, and worse baseline cognition. Although repeated strokes increase dementia risk, a single large or strategically located infarct can produce clinically significant cognitive impairment.

Some degree of cognitive recovery can occur — most commonly within the first 6 months after stroke. However, cumulative vascular brain injury diminishes cognitive reserve, making the brain increasingly vulnerable to further vascular insults and concurrent neurodegenerative pathology. Importantly, risk factors for stroke — including hypertension, hypercholesterolemia, diabetes, cardiac disease, smoking, sedentary behavior, unhealthy diet, obstructive sleep apnea, and obesity — are all potentially modifiable, making secondary prevention after stroke essential for preserving cognitive function.

Subcortical Ischemic Vascular Disease

Advances in neuroimaging have highlighted chronic progressive small vessel ischemic disease as a major contributor to age-related cognitive decline, often without a history of clinical stroke. MRI features include subcortical lacunar infarcts (seen in up to 23% of older individuals, with >90% occurring without TIA or stroke history), white matter hyperintensities (present in >90% of older adults), cerebral microbleeds, microinfarcts, and enlarged perivascular spaces.

These neurovascular unit mechanisms interact synergistically — dysfunction in one pathway amplifies vulnerability in others, accelerating cognitive decline.

Small vessel disease begins to develop as early as midlife, highlighting the need to address vascular risk factors before more severe white matter damage occurs.

White Matter Hyperintensities

MRI T2/FLAIR WMH are the hallmark of small vessel ischemic disease and can be classified by location as periventricular (adjacent to the ventricle wall) or subcortical/deep (surrounded by normal-appearing white matter). Pathologically, they reflect myelin pallor, demyelination, axonal loss, inflammation, microinfarcts, and gliosis. Vascular pathologies underlying WMH include arteriolosclerosis, venous collagenosis, and CAA. Larger baseline WMH volume, hypertension, and smoking are predictors of faster WMH progression. Executive dysfunction and processing speed decline are the primary cognitive domains affected, although memory and global cognition impairment also occur. Mechanisms contributing to WMH-related cognitive decline include regional brain atrophy, thinning of distal cortex connected to WMH via tractography, and disruption of cholinergic pathways. Greater WMH volume is independently associated with increased risk of stroke, dementia, and all-cause mortality. WMH development begins in midlife, underscoring the need for early risk factor management.

Cerebral Microinfarcts

Cerebral microinfarcts are microscopic ischemic lesions (50 μm to several mm) largely invisible on standard MRI. Because standard pathologic sampling examines <0.01% of total brain tissue, total microinfarct burden is vastly underestimated: for every 1–2 microinfarcts found on standard sampling, an estimated 550–1,100 may be present throughout the brain. In a review of 32 autopsy studies (n >10,500), cerebral microinfarcts were found in 62% of patients with vascular dementia, 43% with AD, and 24% of cognitively normal older adults. In the 90+ Study, 51% of the oldest adults had at least one microinfarct at autopsy, and three or more conferred dementia risk comparable to high-burden (Braak V–VI) neurofibrillary tangle pathology.

Microinfarct-related cognitive impairment is independent of concurrent AD pathology and therefore represents an underappreciated but important contributor to age-related decline. Pathologically, microinfarcts are associated with arteriolosclerosis, atherosclerosis, and CAA. Mechanisms of cognitive impairment include focal neuronal death, astrogliosis, blood-brain barrier leakage, and long-range white matter tract disruption via microglia/macrophage migration to the contralateral hemisphere.

Cerebral Amyloid Angiopathy

Cerebral amyloid angiopathy (CAA) is defined by Aβ deposition — predominantly Aβ-40 (in contrast to Aβ-42 in neuritic AD plaques) — in the tunica media and adventitia of cortical and leptomeningeal arterioles. Moderate-to-severe CAA is present in approximately 48% of patients with AD and 23% of population-based older cohorts. CAA is associated with both APOEε4 (more severe CAA) and APOEε2 (vasculopathic changes with increased hemorrhage risk). Progressive vessel wall damage leads to rupture and hemorrhage, with local vascular remodeling driven by blood-brain barrier leakage and perivascular inflammation.

Probable CAA requires clinical presentation (age ≥50, spontaneous ICH, TFNEs, or cognitive impairment) plus at least two lobar hemorrhagic features, or one hemorrhagic feature plus one white matter feature. Possible CAA requires one lobar hemorrhagic feature or one white matter feature.

Most cases of CAA are sporadic; however, rare autosomal dominant forms caused by amyloid precursor protein (APP) mutations exist (Dutch, Italian, Arctic, Iowa, and Flemish variants). These hereditary forms result in younger-onset stroke and cognitive decline with more severe CAA on histologic examination compared with sporadic disease.

CADASIL and Hereditary Arteriopathies

CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) is the most common hereditary cause of VCI, caused by NOTCH3 mutations affecting cysteine residues in epidermal growth factor-like repeat domains. The mutation location partially determines disease severity. CADASIL results in vascular smooth muscle cell degeneration, fibrosis, and vessel stenosis, manifesting as migraine with aura, recurrent subcortical lacunar strokes (mean onset ~49 years, range 20–70), and progressive cognitive decline. MRI shows confluent WMH involving the anterior temporal poles and external capsule — distinct from typical age-related small vessel disease. Treatment considerations include valproic acid for migraine, low-dose aspirin after ischemic stroke, and memantine or donepezil for cognition. Beta-blockers should be avoided for migraine prophylaxis.

CARASIL (HTRA1 mutations) presents with young-onset strokes, cognitive decline, alopecia, and spondylosis. Hereditary arteriopathy should be suspected when MRI white matter disease is out of proportion to age and vascular risk factor burden, particularly with a positive family history.

Mixed Dementia: VCI and Alzheimer Disease

Mixed pathologies are the rule, not the exception, in older adults with dementia. In the Religious Orders Study and Rush Memory and Aging Project, vascular pathology accounted for 32% of the association between age and dementia. Concomitant vascular and neurodegenerative pathologies double the risk of dementia compared with either alone, and having multiple pathologic diagnoses increases both the likelihood and severity of dementia. Cerebrovascular disease decreases the amount of AD and α-synuclein pathology necessary for the clinical expression of dementia — particularly when total AD burden is low.

Several lines of evidence support a link between cerebrovascular risk and AD pathology. A greater increase in cardiovascular risk factors over time raises the risk for both AD and vascular dementia. Midlife dyslipidemia has been associated with greater later-life amyloid deposition on Pittsburgh Compound B-PET, while other vascular risk factors (obesity, smoking, diabetes, hypertension) are associated with AD-independent cortical thinning in regions affected early in AD. Greater circle of Willis atherosclerosis scores correlate with higher neuritic plaque density, neurofibrillary tangle burden, and CAA severity. Pathologically, posterior white matter lesions are more strongly associated with AD pathology, while frontal lesions reflect both vascular and AD etiologies.

Vascular Risk Factors for Cognitive Impairment

Cerebrovascular disease is associated with a constellation of modifiable risk factors, many of which are shared with stroke and coronary artery disease. Effective risk factor modification beginning in midlife is critical — not only to prevent direct vascular brain injury but also to preserve cognitive reserve against concurrent neurodegenerative pathologies. The AHA’s “Life’s Essential 8” framework, updated in 2022, defines metrics for optimal cardiovascular and cerebrovascular health: healthy diet (DASH-style), ≥150 minutes/week of moderate physical activity, nicotine avoidance, 7–9 hours of sleep, BMI <25, non-HDL cholesterol <130, fasting glucose <100 (or HbA1c <5.7%), and blood pressure <120/80 mmHg. The updated framework additionally identifies psychological well-being and social determinants of health as fundamental components of cardiovascular health.

Cardiac Disease and Carotid Stenosis

Among cardiovascular disorders, atrial fibrillation and congestive heart failure have the strongest independent associations with cognitive impairment. Atrial fibrillation is associated with cognitive decline and increased dementia risk, particularly in younger individuals with longer AF duration. Heart failure confers a ~60% increase in dementia risk. Coronary artery disease is associated with a 27% increase in dementia risk, with myocardial infarction linked specifically to vascular (not AD) dementia. In the Rotterdam Study, decreased cerebral perfusion was associated with increased cognitive decline and dementia risk, most pronounced in those with greater WMH burden. High-grade carotid stenosis (≥70%) negatively affects cognition via embolization and hypoperfusion, with CREST-2 demonstrating worse memory performance in affected individuals and potential improvement after carotid endarterectomy.

Perivascular Space and Brain Waste Clearance

The perivascular space — between the endothelial basement membrane and astrocytic end-feet — is integral to the brain’s waste clearance (“glymphatic”) pathway. CSF influx through perivascular channels facilitates clearance of Aβ and tau, a process enhanced during sleep and driven by cardiac-related vascular pulsations and vascular smooth muscle vasomotor activity. MR-visible enlarged perivascular spaces are associated with increased dementia risk: basal ganglia PVS burden correlates with cerebrovascular disease and VCI, while centrum semiovale PVS burden is more strongly associated with AD and CAA.

Prevention and Treatment

Treatment and prevention strategies must be individualized to the specific mechanisms causing vascular brain injury. Even modest improvements in cerebrovascular disease prevention may significantly reduce VCI burden at the population level. The goals include not only preventing direct vascular brain injury but also preserving cognitive reserve so that cognitive function is maintained in the presence of other age-related pathologies that are common in older adults.

Blood pressure control has the strongest evidence base. The SPRINT-MIND study demonstrated that intensive blood pressure lowering (SBP <120 mmHg) was associated with reduced risk for MCI and combined MCI/dementia. Notably, intensive treatment was associated with increased (not decreased) cerebral blood flow on arterial spin labeling MRI. The FINGER trial demonstrated that multidomain intervention targeting diet, exercise, cognitive training, and vascular risk monitoring reduced cognitive decline in at-risk elderly, although two other multidomain studies (MAPT, PreDIVA) failed to show primary benefit — possibly reflecting differences in participant age and intervention intensity.

Health Disparities in VCI

Black and Hispanic/Latino adults are disproportionately affected by AD and related dementias, with 1.5–2 times the dementia risk compared with non-Hispanic White adults. Much of the observed difference can be attributed to a higher prevalence of cardiovascular risk factors in historically marginalized and underserved populations. Older Black adults have greater WMH burden on MRI, higher rates of recurrent stroke and stroke mortality, and higher prevalence of hypertension, diabetes, and smoking. Neuropathologic data from the National Alzheimer’s Coordinating Center demonstrate greater mixed brain pathologies — including cerebrovascular disease — in Black and Hispanic decedents compared with White decedents.

Contributors to health disparities in VCI are varied and include lack of social support, lower educational attainment and socioeconomic status, limited health care access (including preventive care, health maintenance, and acute care), differences in health literacy and cultural norms, and implicit and explicit bias in disease management. Social determinants of health are now recognized by the AHA as a fundamental consideration in the evaluation of cardiovascular health. Addressing health care inequities is a critical and inseparable component of effective VCI prevention and treatment in all older adults.

The largely preventable nature of vascular cognitive impairment makes it one of the most important targets for population-level intervention aimed at preserving cognitive function in aging. Effective strategies must integrate midlife vascular risk factor management, individualized treatment of identified cerebrovascular disease, and equitable access to preventive care across all demographic groups.

References

1. Silbert LC. Vascular cognitive impairment. Continuum (Minneap Minn). 2024;30(6, Dementia):1699–1725.
2. Skrobot OA, Black SE, Chen C, et al. Progress toward standardized diagnosis of vascular cognitive impairment: guidelines from the VICCCS. Alzheimers Dement. 2018;14(3):280–292.
3. El Husseini N, Katzan IL, Rost NS, et al. Cognitive impairment after ischemic and hemorrhagic stroke: AHA/ASA scientific statement. Stroke. 2023;54(6):e272–e291.
4. Rost NS, Brodtmann A, Pase MP, et al. Post-stroke cognitive impairment and dementia. Circ Res. 2022;130(8):1252–1271.
5. Weaver NA, Kuijf HJ, Aben HP, et al. Strategic infarct locations for post-stroke cognitive impairment. Lancet Neurol. 2021;20(6):448–459.
6. Charidimou A, Boulouis G, Frosch MP, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy. Lancet Neurol. 2022;21(8):714–725.
7. Jakel L, De Kort AM, Klijn CJM, et al. Prevalence of cerebral amyloid angiopathy: a systematic review and meta-analysis. Alzheimers Dement. 2022;18(1):10–28.
8. Dupe C, Guey S, Biard L, et al. Phenotypic variability in 446 CADASIL patients: impact of NOTCH3 gene mutation location. J Cereb Blood Flow Metab. 2023;43(1):153–166.
9. Cannistraro RJ, Badi M, Eidelman BH, et al. CNS small vessel disease: a clinical review. Neurology. 2019;92(24):1146–1156.
10. Iadecola C, Duering M, Hachinski V, et al. Vascular cognitive impairment and dementia: JACC scientific expert panel. J Am Coll Cardiol. 2019;73(25):3326–3344.
11. SPRINT MIND Investigators. Effect of intensive vs standard blood pressure control on probable dementia. JAMA. 2019;321(6):553–561.
12. Ngandu T, Lehtisalo J, Solomon A, et al. FINGER: a 2-year multidomain intervention to prevent cognitive decline. Lancet. 2015;385(9984):2255–2263.
13. Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s essential 8: updating the AHA’s construct of cardiovascular health. Circulation. 2022;146(5):e18–e43.
14. Azarpazhooh MR, Avan A, Cipriano LE, et al. Concomitant vascular and neurodegenerative pathologies double the risk of dementia. Alzheimers Dement. 2018;14(2):148–156.
15. Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 2017;134(2):171–186.